Non-alcoholic fatty liver disease (NAFLD) parallels comorbidities such as metabolic syndrome, dyslipidaemia or diabetes. Although NAFLD is very prevalent in overweight-obese individuals (i.e. body mass index≥25kg/m2), recent studies point to the presence of NAFLD in non-obese individuals, for both the Asian (<25kg/m2) and Caucasian (<30kg/m2) populations. This paper discusses the pathogenic pathways and current treatment options of NAFLD in non-obese populations. In this respect, non-obese subjects also need to undergo the medical screening for NAFLD. Across the scientific community, we aim to promote the advancement of knowledge in this emerging field.
Non-alcoholic fatty liver disease in non-obese individuals: Prevalence, pathogenesis and treatment
Molina-Molina E.;Portincasa P.
2019-01-01
Abstract
Non-alcoholic fatty liver disease (NAFLD) parallels comorbidities such as metabolic syndrome, dyslipidaemia or diabetes. Although NAFLD is very prevalent in overweight-obese individuals (i.e. body mass index≥25kg/m2), recent studies point to the presence of NAFLD in non-obese individuals, for both the Asian (<25kg/m2) and Caucasian (<30kg/m2) populations. This paper discusses the pathogenic pathways and current treatment options of NAFLD in non-obese populations. In this respect, non-obese subjects also need to undergo the medical screening for NAFLD. Across the scientific community, we aim to promote the advancement of knowledge in this emerging field.| File | Dimensione | Formato | |
|---|---|---|---|
|
Molina-Molina-2019-Non-alcoholic fatty liver d.pdf
non disponibili
Tipologia:
Documento in Versione Editoriale
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
1.2 MB
Formato
Adobe PDF
|
1.2 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
